Biotechnology

A new DoD-funded trial combines a biologic drug with a plant-based supplement, aiming to break treatment barriers for ulcerative colitis, a major military issue.

The 'Beauty in Black' star, whose character has prostate cancer, is now a Global Ambassador for ZERO, tackling the disease's deadly toll on Black men.

Red Light Holland is deploying advanced AI from Kala Bio to accelerate its botanical psilocybin program, signaling a new high-tech era for mental health.

Amid massive layoffs and AI-driven shifts, the life sciences industry faces a structural crisis. Blue Matter's new practice offers a roadmap to survive.

The company launches new research assays for pTau217, entering a competitive field aimed at replacing invasive tests with a simple blood draw.

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

With a major Series B financing, Crossbow advances its TCR-mimetic therapies, aiming to unlock a new frontier in the fight against a broad range of cancers.

Biotech firm ProMIS Neurosciences reveals novel vaccine data for ALS and Parkinson's, using a platform that selectively targets only toxic proteins.

New data suggests Phanes Therapeutics' bispecific antibody may overcome major side effects of CD47 inhibitors while showing promise in tough GI cancers.

Cingulate Inc. faces a critical FDA decision for its novel ADHD drug, but manufacturing queries and a tight cash runway create a high-stakes countdown.

Artelo Biosciences is testing a novel cannabinoid drug for glaucoma, aiming to protect vision in a way current treatments can't—all without diluting shares.

With veteran leader Brian McKelligon at the helm, Infinity Bio aims to commercialize its powerful MIPSA platform and redefine precision medicine.

A landmark deal between Australia's VVMF and UK's OXB aims to create a new cell and gene therapy manufacturing hub for the booming Asia-Pacific market.

A new partnership will leverage genetically engineered mice to create novel antibody drugs, potentially unlocking treatments for cancer and brain diseases.

With a massive $68.7M seed round and novel T-cell engager tech, Shanghai's Excalipoint is pioneering a new model for rapid drug development.

ACTO's new AI suite automates workflows, promising to boost efficiency and compliance for pharma and medtech field professionals while keeping humans in control.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

With a new CEO and Chair, IsomAb is advancing a disease-modifying drug for 9 million angina patients, eyeing a major Series A fundraise.

A new partnership seeks to conquer C. difficile, a deadly hospital infection that has stumped pharma giants, by advancing a novel dual-action vaccine.

A new collaboration will use innovative protein binders to fight animal disease, bolstering global food security and public health under the One Health framework.